Ideal for: NOS and VEGF signaling, angiogenesis inhibitors, DNA methylation studies

OCI-AML2 is an acute myeloid leukemia cell line. OCI-AML2 cells express the retinoic alpha receptor (RAR). Additionally, they contain a DNA methyltransferase 3 alpha (DNMT3A) gene which plays a role in cellular epigenetics. OCI-AML2 cells express VEGF receptor-2 (VGEFR2/Flk-1/KDR), eNOS, and the VEGF ligand involved in malignant hematopoiesis, also known as angiogenesis1.

OCI-AML2 cells have been used to demonstrate that inhibitors of VEGF, Flk-1/KDR, and PI3K lead to a decrease in AKT kinase and nitric oxide synthase (NOS) signaling. It has been shown that decreased NOS activity leads to clonal cell growth and some induction of apoptosis1.

Request A Proposal
Download Publications

Enabling Case Study: OCI-AML2 Tumor Kinetics in OncoRat

The OncoRat demonstrated a 100% engraftment rate for the OCI-AML2 xenograft model, providing an ideal host for OCI-AML2 tumor biology.

OCI-AML2 products & services

  • Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
  • Weekly or bi-weekly tumor sampling via fine need aspiration (FNA). For longitudinal evaluation of drug exposure, histology and gene expression.
  • OncoRats off-the-shelf for engraftment at the customers facility.
  1. Koistinen P, Siitonen T, Mantymaa P, et al. Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system. Leukemia. 2001;15(9):1433-1441.